Top Markets
Coin of the day
StageZero Life Sciences Ltd. StageZero Life Sciences Ltd.

StageZero Life Sciences Ltd.

SZLS
株式のランク #36214
StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise... StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise specializing in the development and market release of advanced molecular diagnostic tests. These innovative solutions are designed for the proactive detection of diseases and individualized health management, with a particular emphasis on oncology-related conditions across North America. Central to its operations is the proprietary Sentinel Principle platform, which enables the identification of novel biomarkers directly from whole blood samples. Its flagship product, Aristotle, exemplifies this innovation; it's a comprehensive multi-cancer panel that simultaneously screens for numerous cancers from a single blood draw, boasting impressive sensitivity and specificity for each identified malignancy. Beyond Aristotle, the company's portfolio includes ColonSentry, a blood-based test gauging colorectal cancer risk; COVID-19 PCR testing and general blood analysis services; the Prostate Health Index for prostate cancer screening; and BreastSentry, designed to evaluate a woman's susceptibility to breast cancer. Established in 1998, StageZero Life Sciences Ltd. maintains its headquarters in Richmond Hill, Canada.
株価
$0.02770208
最終同期: 2025-03-10
時価総額
$2.92M
変化(1日)
-0.46%
変化(1年)
0.00%
CA
取引 StageZero Life Sciences Ltd. (SZLS)

カテゴリー

StageZero Life Sciences Ltd.(SZLS)の配当利回りの履歴
StageZero Life Sciences Ltd.(銘柄コード: SZLS)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
StageZero Life Sciences Ltd.(SZLS)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)